Gut microbes promote chemoradiotherapy resistance via metabolic cross-feeding

Chi Chun Wong; Winnie Fong; Jun Yu

doi:10.1016/j.ccell.2022.11.017

Gut microbes promote chemoradiotherapy resistance via metabolic cross-feeding

Cancer Cell. 2023 Jan 9;41(1):12-14. doi: 10.1016/j.ccell.2022.11.017. Epub 2022 Dec 22.

Authors

Chi Chun Wong¹, Winnie Fong¹, Jun Yu²

Affiliations

¹ Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.
² Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China. Electronic address: junyu@cuhk.edu.hk.

PMID: 36563683
DOI: 10.1016/j.ccell.2022.11.017

Abstract

Gut microorganisms can modulate response to cancer therapies. In this issue of Cancer Cell, Teng et al. trace the gut bacteria and metabolites in rectal cancer patients over the course of neoadjuvant chemoradiotherapy and identify Bacteroides vulgatus as a driver bacterium of therapeutic resistance by supplying tumors with nucleotides.

Publication types

Comment

MeSH terms

Chemoradiotherapy
Gastrointestinal Microbiome*
Humans
Neoadjuvant Therapy
Rectal Neoplasms* / drug therapy